infohep news

• NAFLD

  Diabetes raises the risk of liver damage in people with HIV

  Keith Alcorn / 21 September 2020

  Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had non-alcoholic steatohepatitis (NASH) and 39 of 116 had stage F3 or F4 fibrosis, and advanced ...

• Hepatocellular carcinoma (HCC)

  Models can help predict liver cancer in people cured of hepatitis C

  Liz Highleyman / 17 September 2020

  Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ...

• Coronavirus

  International registries provide more information about COVID-19 and liver disease

  Liz Highleyman / 17 September 2020

  People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver transplants do not appear to be at greater ...

• Experimental treatments for NASH/NAFLD

  Aldafermin reduces liver fat in phase 2 study

  Keith Alcorn / 14 September 2020

  Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ...

• NAFLD

  Fatty liver disease affects one in four in Europe, study estimates

  Keith Alcorn / 07 September 2020

  Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ...